Literature DB >> 1823629

Action of cysteaminylphenols on human melanoma cells in vivo and in vitro: 4-S-cysteaminylphenol binds protein disulphide isomerase.

P G Parsons1, D Favier, M McEwan, H Takahashi, K Jimbow, S Ito.   

Abstract

Systemically administered 4-S-cysteaminylphenol (4-S-CAP) and N-acetyl-4-S-CAP inhibited the growth of xenografts of a human melanoma cell line but not of an ovarian tumour cell line. No selective cytotoxicity for melanoma cells was observed in culture, however. Further study of the in vitro mechanism of 4-S-CAP toxicity showed minimal inhibition of tyrosinase activity or DNA, RNA and protein synthesis, and there was no phase-specific arrest of the cell cycle. However, expression of an 80 kD melanosomal antigen was decreased. Cytotoxicity of 4-S-CAP in culture was decreased by simultaneous treatment with a monoamine oxidase inhibitor. An affinity column prepared from 4-S-CAP retained several proteins from a melanoma cell lysate. One protein, found also in HeLa cells, was identified by N-terminal sequencing as protein disulphide isomerase, a molecule which has multiple roles in the modification of secretory proteins. These results identify a protein target for 4-S-CAP as one possible mechanism of cytotoxicity.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1823629     DOI: 10.1097/00008390-199106000-00004

Source DB:  PubMed          Journal:  Melanoma Res        ISSN: 0960-8931            Impact factor:   3.599


  2 in total

1.  Melanoma-Targeted Chemothermotherapy and In Situ Peptide Immunotherapy through HSP Production by Using Melanogenesis Substrate, NPrCAP, and Magnetite Nanoparticles.

Authors:  Kowichi Jimbow; Yasue Ishii-Osai; Shosuke Ito; Yasuaki Tamura; Akira Ito; Akihiro Yoneta; Takafumi Kamiya; Toshiharu Yamashita; Hiroyuki Honda; Kazumasa Wakamatsu; Katsutoshi Murase; Satoshi Nohara; Eiichi Nakayama; Takeo Hasegawa; Itsuo Yamamoto; Takeshi Kobayashi
Journal:  J Skin Cancer       Date:  2013-02-21

2.  Anti-tumour activity in vitro and in vivo of selective differentiating agents containing hydroxamate.

Authors:  L Qiu; M J Kelso; C Hansen; M L West; D P Fairlie; P G Parsons
Journal:  Br J Cancer       Date:  1999-06       Impact factor: 7.640

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.